Understand the source comparison
Melatonin Myths Debunked: Clinical vs Retail Reality Comparison
The table below contrasts what controlled clinical trials demonstrate versus the retail supplement landscape most consumers encounter. Effective dose for sleep-onset latency reduction 0.3–1mg produces mean 18–25 minute reduction in sleep-onset latency (Journal
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts what controlled clinical trials demonstrate versus the retail supplement landscape most consumers encounter.
- Effective dose for sleep-onset latency reduction
- 0.3–1mg produces mean 18–25 minute reduction in sleep-onset latency (Journal of Clinical Sleep Medicine, 2023)
- Most products contain 3–10mg per dose; some formulations exceed 20mg
- Retail products are dosed 10–30× higher than clinical efficacy range. More is not better
- Dependency and tolerance risk
- No receptor downregulation at physiological doses; no withdrawal syndrome in trials up to 24 months (Sleep Medicine Reviews, 2024)
- Product labels often include warnings about 'consult your doctor before long-term use'
- Warnings reflect liability caution, not pharmacological risk. Melatonin has no addiction potential
- Natural production suppression
- Endogenous melatonin synthesis unchanged after 6 months of nightly 0.5mg use; DLMO timing and amplitude normal post-washout (Sleep, 2022)
- Persistent online claims that 'your body stops making melatonin if you supplement'
- Myth. Pineal output is light-regulated, not feedback-inhibited by exogenous melatonin
- Optimal timing for circadian phase shift
- 60–90 minutes before desired sleep time in dim light environment; earlier dosing shifts phase forward without improving sleep-onset latency
- No standardized guidance on product labels; many users take melatonin immediately before bed
- Timing errors negate efficacy. Melatonin is not a knockout drug, it's a circadian signal
- Next-day sedation and cognitive impairment
- Doses >3mg produce measurable next-day grogginess, reduced alertness, and impaired reaction time in morning testing (Chronobiology International, 2023)
- High-dose products marketed as 'extra strength' or 'maximum potency'
- Supraphysiological doses create hangover effects absent at 0.3–1mg range
- Sleep architecture and REM duration
- Low-dose melatonin (0.5mg) increases REM duration by 12–15% and improves sleep efficiency; high-dose (5mg) reduces REM and increases Stage 1 fragmentation
- No dose-response information provided to consumers
- Higher doses impair sleep quality metrics despite subjective sedation